EUVIMEDEUVIMED entdecken
Crossref

Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy

Fengjuan Xie, Shasha Tang, Ye Zhang, Yinbing Zhao, Yingying Lin, Yining Yao, Meiyan Wang iD, Zhengying Gu, Jingjing Wan iD

ACS Nano · 2024

DOI: 10.1021/acsnano.3c09968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2024. Verfasst von Fengjuan Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, People's Republic of China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality, Natural Science Foundation of Chongqing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmunotherapyHumansAnimalsMiceLigandsApoptosisPeptidesCell Line, Tumor

Stichwörter der Autor:innen

PD-L1 nanoinhibitorcancer chemo-immunotherapydrug deliveryimmune checkpoint blockade (ICB)peptide stability

Substanzen

B7-H1 AntigenLigandsPeptides

Autor:innen und Institutionen

  • School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, People's Republic of China.
  • Department of Breast Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, People's Republic of China.
  • School of Medicine, Shanghai University, Shanghai 200444, People's Republic of China.
  • Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, People's Republic of China.
  • Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, People's Republic of China.

ORCID-Profile: Meiyan Wang, Jingjing Wan

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China
  • State Key Laboratory of Oncogenes and Related Genes

Zitieren

APA

Xie, F., Tang, S., Zhang, Y., Zhao, Y., Lin, Y., Yao, Y., Wang, M., Gu, Z., & Wan, J. (2024). Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.3c09968

Vancouver

Xie F, Tang S, Zhang Y, Zhao Y, Lin Y, Yao Y, et al. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy. ACS Nano. 2024. doi:10.1021/acsnano.3c09968

BibTeX
@article{Xie2024,
  author = {Xie, Fengjuan and Tang, Shasha and Zhang, Ye and Zhao, Yinbing and Lin, Yingying and Yao, Yining and Wang, Meiyan and Gu, Zhengying and Wan, Jingjing},
  title = {Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy},
  journal = {ACS Nano},
  year = {2024},
  doi = {10.1021/acsnano.3c09968}
}
Kostenlos starten →